Is NEU.AX overvalued or undervalued?

NEU.AX currently has a P/E ratio of 127.61. Relative to the sector average of 41.10, this suggests the stock may be overvalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Neuren Pharmaceuticals Limited stock?

Neuren Pharmaceuticals Limited trades on ASX. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of NEU.AX?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying NEU.AX protect my money against local inflation?

Many investors in Latin America buy international stocks like NEU.AX to protect their purchasing power. Because NEU.AX is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy NEU.AX shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is NEU.AX a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well NEU.AX diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocksNEU.AX

Neuren Pharmaceuticals Limited

A$20.20-A$0.06-0.30%

ASX / AUD

Market cap

A$2.6B

P/E

127.6

EPS (TTM)

A$0.11

Dividend yield

0.74%

Beta

1.59

1Y return

-5.25%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$2M2021

$10M2022

$158M2023

$132M2024

$43M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity—
Current ratio46.45
Cash ratio3.75
Net margin29.1%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

NEU.AX127.6
Healthcare sector median41.1
S&P 50022.0

Trades about 210% above its sector, the market expects faster growth.

Ratios

PEG-1.48
Price to book7.68
EPS (TTM)A$0.11
Payout ratio0%
FCF yield5.25%

Range & risk

A$11.00A$23.76

Trading in the upper third of its 52-week band

Beta1.59

Profile

What Neuren Pharmaceuticals Limited actually does

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Hawthorn East, Australia.

CEO

Jonathan Charles Pilcher

Employees

Headquarters

Hawthorn East, VIC

Founded

2005-02-01

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save NEU.AX and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

NEU.AX has a beta of 1.59, which indicates how sensitive it has historically been to movements in its broader market. A beta above 1 suggests higher relative volatility than the market. Beta is based on historical data and does not predict future performance.

Neuren Pharmaceuticals Limited